All In Biotech

NDA 207145 · Mdd US

Xadago

Safinamide Mesylate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Aug 6, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 21, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

11 Phase 3, 1 recruiting

FAERS reports

1,386

1,086 serious, 175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes ( 1 )

Mechanism: The precise mechanism by which XADAGO exerts its therapeutic effects in PD is unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 21, 2017 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • XADAGO · SAFINAMIDE MESYLATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
  • XADAGO · SAFINAMIDE MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Safinamide" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fall177
  • dyskinesia162
  • hallucination159
  • death108
  • on and off phenomenon108
  • gait disturbance104
  • parkinson^s disease98
  • drug ineffective95
  • tremor89
  • fatigue82
  • freezing phenomenon78
  • somnolence73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201624
201757
2018112
2019152
2020158
2021144
2022142
2023117
2024136
2025173
2026171

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xadago (Safinamide Mesylate)

2024 spending

$7.7M

Beneficiaries

759

4,385 claims

Per beneficiary

$10,116

$37.32 per unit

View as table
YearSpending
2020$10,536,450
2021$10,886,772
2022$10,622,045
2023$9,872,595
2024$7,677,986

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 52 on PubMed

Sponsor: Mdd US

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.